nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—Cytochrome P450 2C8 Inducers—Phenytoin—epilepsy syndrome	0.127	0.214	CiPCiCtD
Dabrafenib—ABCG2—epilepsy syndrome	0.0742	0.706	CbGaD
Dabrafenib—Cytochrome P450 2B6 Inducers—Carbamazepine—epilepsy syndrome	0.0683	0.115	CiPCiCtD
Dabrafenib—Cytochrome P450 2C19 Inducers—Carbamazepine—epilepsy syndrome	0.0683	0.115	CiPCiCtD
Dabrafenib—Cytochrome P450 2C9 Inducers—Carbamazepine—epilepsy syndrome	0.0683	0.115	CiPCiCtD
Dabrafenib—Cytochrome P450 2B6 Inducers—Phenytoin—epilepsy syndrome	0.0609	0.103	CiPCiCtD
Dabrafenib—Cytochrome P450 2C19 Inducers—Phenytoin—epilepsy syndrome	0.0609	0.103	CiPCiCtD
Dabrafenib—Cytochrome P450 2C9 Inducers—Phenytoin—epilepsy syndrome	0.0609	0.103	CiPCiCtD
Dabrafenib—Cytochrome P450 3A4 Inducers—Carbamazepine—epilepsy syndrome	0.0427	0.0719	CiPCiCtD
Dabrafenib—Cytochrome P450 3A4 Inducers—Topiramate—epilepsy syndrome	0.0363	0.0612	CiPCiCtD
Dabrafenib—ABCB1—epilepsy syndrome	0.0309	0.294	CbGaD
Dabrafenib—CYP2C8—Trimethadione—epilepsy syndrome	0.00973	0.0589	CbGbCtD
Dabrafenib—CYP2C8—Fosphenytoin—epilepsy syndrome	0.00915	0.0554	CbGbCtD
Dabrafenib—SLC22A8—Valproic Acid—epilepsy syndrome	0.00856	0.0519	CbGbCtD
Dabrafenib—SLC22A6—Acetazolamide—epilepsy syndrome	0.00798	0.0484	CbGbCtD
Dabrafenib—ABCB1—Levetiracetam—epilepsy syndrome	0.00774	0.0469	CbGbCtD
Dabrafenib—CYP2C8—Carbamazepine—epilepsy syndrome	0.00657	0.0398	CbGbCtD
Dabrafenib—CYP2C8—Primidone—epilepsy syndrome	0.00614	0.0372	CbGbCtD
Dabrafenib—SLC22A6—Valproic Acid—epilepsy syndrome	0.00597	0.0361	CbGbCtD
Dabrafenib—CYP2C8—Phenytoin—epilepsy syndrome	0.00589	0.0357	CbGbCtD
Dabrafenib—CYP2C8—Propofol—epilepsy syndrome	0.0055	0.0333	CbGbCtD
Dabrafenib—ABCB1—Clobazam—epilepsy syndrome	0.00537	0.0325	CbGbCtD
Dabrafenib—CYP2C8—Phenobarbital—epilepsy syndrome	0.00525	0.0318	CbGbCtD
Dabrafenib—ABCB1—Lamotrigine—epilepsy syndrome	0.00517	0.0313	CbGbCtD
Dabrafenib—CYP2C8—Diazepam—epilepsy syndrome	0.00498	0.0302	CbGbCtD
Dabrafenib—ABCB1—Carbamazepine—epilepsy syndrome	0.00445	0.0269	CbGbCtD
Dabrafenib—CYP3A4—Oxcarbazepine—epilepsy syndrome	0.00424	0.0257	CbGbCtD
Dabrafenib—ABCB1—Phenytoin—epilepsy syndrome	0.00399	0.0242	CbGbCtD
Dabrafenib—CYP3A4—Trimethadione—epilepsy syndrome	0.00395	0.0239	CbGbCtD
Dabrafenib—CYP3A4—Felbamate—epilepsy syndrome	0.00395	0.0239	CbGbCtD
Dabrafenib—CYP2C8—Valproic Acid—epilepsy syndrome	0.00393	0.0238	CbGbCtD
Dabrafenib—CYP3A4—Fosphenytoin—epilepsy syndrome	0.00371	0.0225	CbGbCtD
Dabrafenib—ABCB1—Phenobarbital—epilepsy syndrome	0.00356	0.0215	CbGbCtD
Dabrafenib—ABCB1—Midazolam—epilepsy syndrome	0.00351	0.0212	CbGbCtD
Dabrafenib—ABCB1—Diazepam—epilepsy syndrome	0.00337	0.0204	CbGbCtD
Dabrafenib—CYP3A4—Clonazepam—epilepsy syndrome	0.00335	0.0203	CbGbCtD
Dabrafenib—CYP3A4—Clobazam—epilepsy syndrome	0.00322	0.0195	CbGbCtD
Dabrafenib—CYP3A4—Rufinamide—epilepsy syndrome	0.00273	0.0166	CbGbCtD
Dabrafenib—CYP3A4—Carbamazepine—epilepsy syndrome	0.00267	0.0161	CbGbCtD
Dabrafenib—CYP3A4—Primidone—epilepsy syndrome	0.00249	0.0151	CbGbCtD
Dabrafenib—CYP3A4—Phenytoin—epilepsy syndrome	0.00239	0.0145	CbGbCtD
Dabrafenib—CYP3A4—Propofol—epilepsy syndrome	0.00223	0.0135	CbGbCtD
Dabrafenib—CYP3A4—Acetazolamide—epilepsy syndrome	0.00213	0.0129	CbGbCtD
Dabrafenib—CYP3A4—Phenobarbital—epilepsy syndrome	0.00213	0.0129	CbGbCtD
Dabrafenib—CYP3A4—Midazolam—epilepsy syndrome	0.0021	0.0127	CbGbCtD
Dabrafenib—CYP3A4—Diazepam—epilepsy syndrome	0.00202	0.0122	CbGbCtD
Dabrafenib—CYP3A4—Zonisamide—epilepsy syndrome	0.00197	0.0119	CbGbCtD
Dabrafenib—CYP3A4—Valproic Acid—epilepsy syndrome	0.00159	0.00965	CbGbCtD
Dabrafenib—CYP3A4—Topiramate—epilepsy syndrome	0.00144	0.0087	CbGbCtD
Dabrafenib—NEK11—medulla oblongata—epilepsy syndrome	0.000912	0.0686	CbGeAlD
Dabrafenib—LIMK1—telencephalon—epilepsy syndrome	0.000831	0.0624	CbGeAlD
Dabrafenib—RAF1—hindbrain—epilepsy syndrome	0.000672	0.0505	CbGeAlD
Dabrafenib—NEK11—cerebellum—epilepsy syndrome	0.000645	0.0485	CbGeAlD
Dabrafenib—LIMK1—midbrain—epilepsy syndrome	0.000597	0.0448	CbGeAlD
Dabrafenib—NEK11—brain—epilepsy syndrome	0.000524	0.0394	CbGeAlD
Dabrafenib—SIK1—forebrain—epilepsy syndrome	0.000467	0.0351	CbGeAlD
Dabrafenib—LIMK1—cerebellum—epilepsy syndrome	0.000461	0.0347	CbGeAlD
Dabrafenib—SIK1—telencephalon—epilepsy syndrome	0.00043	0.0323	CbGeAlD
Dabrafenib—RAF1—brainstem—epilepsy syndrome	0.000385	0.029	CbGeAlD
Dabrafenib—LIMK1—brain—epilepsy syndrome	0.000375	0.0282	CbGeAlD
Dabrafenib—RAF1—forebrain—epilepsy syndrome	0.000372	0.028	CbGeAlD
Dabrafenib—BRAF—midbrain—epilepsy syndrome	0.000369	0.0277	CbGeAlD
Dabrafenib—RAF1—telencephalon—epilepsy syndrome	0.000342	0.0257	CbGeAlD
Dabrafenib—SIK1—medulla oblongata—epilepsy syndrome	0.000338	0.0254	CbGeAlD
Dabrafenib—SIK1—spinal cord—epilepsy syndrome	0.000301	0.0226	CbGeAlD
Dabrafenib—BRAF—cerebellum—epilepsy syndrome	0.000285	0.0214	CbGeAlD
Dabrafenib—RAF1—medulla oblongata—epilepsy syndrome	0.000269	0.0202	CbGeAlD
Dabrafenib—SIK1—head—epilepsy syndrome	0.000267	0.0201	CbGeAlD
Dabrafenib—SIK1—nervous system—epilepsy syndrome	0.000254	0.0191	CbGeAlD
Dabrafenib—RAF1—midbrain—epilepsy syndrome	0.000246	0.0185	CbGeAlD
Dabrafenib—SIK1—central nervous system—epilepsy syndrome	0.000244	0.0184	CbGeAlD
Dabrafenib—RAF1—spinal cord—epilepsy syndrome	0.00024	0.018	CbGeAlD
Dabrafenib—SIK1—cerebellum—epilepsy syndrome	0.000239	0.0179	CbGeAlD
Dabrafenib—BRAF—brain—epilepsy syndrome	0.000232	0.0174	CbGeAlD
Dabrafenib—RAF1—head—epilepsy syndrome	0.000213	0.016	CbGeAlD
Dabrafenib—RAF1—nervous system—epilepsy syndrome	0.000202	0.0152	CbGeAlD
Dabrafenib—RAF1—central nervous system—epilepsy syndrome	0.000194	0.0146	CbGeAlD
Dabrafenib—SIK1—brain—epilepsy syndrome	0.000194	0.0146	CbGeAlD
Dabrafenib—RAF1—cerebellum—epilepsy syndrome	0.00019	0.0143	CbGeAlD
Dabrafenib—RAF1—brain—epilepsy syndrome	0.000154	0.0116	CbGeAlD
Dabrafenib—SLC22A6—brain—epilepsy syndrome	0.00015	0.0113	CbGeAlD
Dabrafenib—ABCG2—telencephalon—epilepsy syndrome	0.000141	0.0106	CbGeAlD
Dabrafenib—SLC22A8—head—epilepsy syndrome	0.000124	0.0093	CbGeAlD
Dabrafenib—SLC22A8—nervous system—epilepsy syndrome	0.000117	0.00882	CbGeAlD
Dabrafenib—SLC22A8—central nervous system—epilepsy syndrome	0.000113	0.00849	CbGeAlD
Dabrafenib—ABCG2—medulla oblongata—epilepsy syndrome	0.000111	0.00835	CbGeAlD
Dabrafenib—ABCG2—midbrain—epilepsy syndrome	0.000102	0.00763	CbGeAlD
Dabrafenib—ABCG2—spinal cord—epilepsy syndrome	9.91e-05	0.00745	CbGeAlD
Dabrafenib—SLC22A8—brain—epilepsy syndrome	8.97e-05	0.00674	CbGeAlD
Dabrafenib—ABCG2—cerebellum—epilepsy syndrome	7.86e-05	0.00591	CbGeAlD
Dabrafenib—ABCB1—forebrain—epilepsy syndrome	7.58e-05	0.0057	CbGeAlD
Dabrafenib—ABCB1—telencephalon—epilepsy syndrome	6.97e-05	0.00524	CbGeAlD
Dabrafenib—CYP2C8—brain—epilepsy syndrome	6.56e-05	0.00493	CbGeAlD
Dabrafenib—ABCG2—brain—epilepsy syndrome	6.38e-05	0.0048	CbGeAlD
Dabrafenib—CYP3A4—nervous system—epilepsy syndrome	5.82e-05	0.00437	CbGeAlD
Dabrafenib—CYP3A4—central nervous system—epilepsy syndrome	5.6e-05	0.00421	CbGeAlD
Dabrafenib—ABCB1—medulla oblongata—epilepsy syndrome	5.48e-05	0.00412	CbGeAlD
Dabrafenib—ABCB1—midbrain—epilepsy syndrome	5.01e-05	0.00376	CbGeAlD
Dabrafenib—ABCB1—spinal cord—epilepsy syndrome	4.89e-05	0.00367	CbGeAlD
Dabrafenib—ABCB1—head—epilepsy syndrome	4.34e-05	0.00326	CbGeAlD
Dabrafenib—ABCB1—nervous system—epilepsy syndrome	4.12e-05	0.0031	CbGeAlD
Dabrafenib—ABCB1—central nervous system—epilepsy syndrome	3.96e-05	0.00298	CbGeAlD
Dabrafenib—ABCB1—cerebellum—epilepsy syndrome	3.87e-05	0.00291	CbGeAlD
Dabrafenib—ABCB1—brain—epilepsy syndrome	3.15e-05	0.00237	CbGeAlD
Dabrafenib—Headache—Midazolam—epilepsy syndrome	3.07e-05	0.000449	CcSEcCtD
Dabrafenib—Pruritus—Felbamate—epilepsy syndrome	3.07e-05	0.000449	CcSEcCtD
Dabrafenib—Abdominal pain—Carbamazepine—epilepsy syndrome	3.07e-05	0.000449	CcSEcCtD
Dabrafenib—Body temperature increased—Carbamazepine—epilepsy syndrome	3.07e-05	0.000449	CcSEcCtD
Dabrafenib—Diarrhoea—Diazepam—epilepsy syndrome	3.07e-05	0.000449	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Lamotrigine—epilepsy syndrome	3.07e-05	0.000449	CcSEcCtD
Dabrafenib—Rash—Levetiracetam—epilepsy syndrome	3.05e-05	0.000447	CcSEcCtD
Dabrafenib—Anaemia—Pregabalin—epilepsy syndrome	3.05e-05	0.000447	CcSEcCtD
Dabrafenib—Dermatitis—Levetiracetam—epilepsy syndrome	3.05e-05	0.000446	CcSEcCtD
Dabrafenib—Asthenia—Zonisamide—epilepsy syndrome	3.05e-05	0.000446	CcSEcCtD
Dabrafenib—Mental disorder—Gabapentin—epilepsy syndrome	3.05e-05	0.000446	CcSEcCtD
Dabrafenib—Dry mouth—Valproic Acid—epilepsy syndrome	3.04e-05	0.000445	CcSEcCtD
Dabrafenib—Headache—Levetiracetam—epilepsy syndrome	3.03e-05	0.000444	CcSEcCtD
Dabrafenib—Malnutrition—Gabapentin—epilepsy syndrome	3.03e-05	0.000443	CcSEcCtD
Dabrafenib—Erythema—Gabapentin—epilepsy syndrome	3.03e-05	0.000443	CcSEcCtD
Dabrafenib—Hypersensitivity—Clonazepam—epilepsy syndrome	3.01e-05	0.000441	CcSEcCtD
Dabrafenib—Dizziness—Vigabatrin—epilepsy syndrome	3.01e-05	0.000441	CcSEcCtD
Dabrafenib—Pruritus—Zonisamide—epilepsy syndrome	3e-05	0.00044	CcSEcCtD
Dabrafenib—Hypersensitivity—Phenytoin—epilepsy syndrome	2.99e-05	0.000438	CcSEcCtD
Dabrafenib—Oedema—Valproic Acid—epilepsy syndrome	2.98e-05	0.000436	CcSEcCtD
Dabrafenib—Hypersensitivity—Oxcarbazepine—epilepsy syndrome	2.98e-05	0.000436	CcSEcCtD
Dabrafenib—Nausea—Propofol—epilepsy syndrome	2.97e-05	0.000435	CcSEcCtD
Dabrafenib—Vomiting—Fosphenytoin—epilepsy syndrome	2.97e-05	0.000435	CcSEcCtD
Dabrafenib—Diarrhoea—Felbamate—epilepsy syndrome	2.97e-05	0.000434	CcSEcCtD
Dabrafenib—Abdominal pain—Lamotrigine—epilepsy syndrome	2.96e-05	0.000434	CcSEcCtD
Dabrafenib—Body temperature increased—Lamotrigine—epilepsy syndrome	2.96e-05	0.000434	CcSEcCtD
Dabrafenib—Dizziness—Diazepam—epilepsy syndrome	2.96e-05	0.000434	CcSEcCtD
Dabrafenib—Infection—Valproic Acid—epilepsy syndrome	2.96e-05	0.000433	CcSEcCtD
Dabrafenib—Leukopenia—Pregabalin—epilepsy syndrome	2.95e-05	0.000432	CcSEcCtD
Dabrafenib—Rash—Fosphenytoin—epilepsy syndrome	2.94e-05	0.000431	CcSEcCtD
Dabrafenib—Dermatitis—Fosphenytoin—epilepsy syndrome	2.94e-05	0.000431	CcSEcCtD
Dabrafenib—Haemoglobin—Topiramate—epilepsy syndrome	2.94e-05	0.00043	CcSEcCtD
Dabrafenib—Asthenia—Clonazepam—epilepsy syndrome	2.94e-05	0.00043	CcSEcCtD
Dabrafenib—Back pain—Gabapentin—epilepsy syndrome	2.93e-05	0.000429	CcSEcCtD
Dabrafenib—Headache—Fosphenytoin—epilepsy syndrome	2.93e-05	0.000428	CcSEcCtD
Dabrafenib—Haemorrhage—Topiramate—epilepsy syndrome	2.92e-05	0.000428	CcSEcCtD
Dabrafenib—Nervous system disorder—Valproic Acid—epilepsy syndrome	2.92e-05	0.000428	CcSEcCtD
Dabrafenib—Thrombocytopenia—Valproic Acid—epilepsy syndrome	2.92e-05	0.000427	CcSEcCtD
Dabrafenib—Asthenia—Phenytoin—epilepsy syndrome	2.92e-05	0.000427	CcSEcCtD
Dabrafenib—Nausea—Midazolam—epilepsy syndrome	2.91e-05	0.000426	CcSEcCtD
Dabrafenib—Muscle spasms—Gabapentin—epilepsy syndrome	2.91e-05	0.000426	CcSEcCtD
Dabrafenib—Diarrhoea—Zonisamide—epilepsy syndrome	2.9e-05	0.000425	CcSEcCtD
Dabrafenib—Asthenia—Oxcarbazepine—epilepsy syndrome	2.9e-05	0.000425	CcSEcCtD
Dabrafenib—Pruritus—Clonazepam—epilepsy syndrome	2.89e-05	0.000424	CcSEcCtD
Dabrafenib—Vomiting—Vigabatrin—epilepsy syndrome	2.89e-05	0.000424	CcSEcCtD
Dabrafenib—Skin disorder—Valproic Acid—epilepsy syndrome	2.89e-05	0.000424	CcSEcCtD
Dabrafenib—Urinary tract disorder—Topiramate—epilepsy syndrome	2.89e-05	0.000423	CcSEcCtD
Dabrafenib—Oedema peripheral—Topiramate—epilepsy syndrome	2.88e-05	0.000422	CcSEcCtD
Dabrafenib—Hyperhidrosis—Valproic Acid—epilepsy syndrome	2.88e-05	0.000422	CcSEcCtD
Dabrafenib—Cough—Pregabalin—epilepsy syndrome	2.88e-05	0.000422	CcSEcCtD
Dabrafenib—Pruritus—Phenytoin—epilepsy syndrome	2.88e-05	0.000421	CcSEcCtD
Dabrafenib—Connective tissue disorder—Topiramate—epilepsy syndrome	2.87e-05	0.000421	CcSEcCtD
Dabrafenib—Nausea—Levetiracetam—epilepsy syndrome	2.87e-05	0.000421	CcSEcCtD
Dabrafenib—Rash—Vigabatrin—epilepsy syndrome	2.87e-05	0.00042	CcSEcCtD
Dabrafenib—Dizziness—Felbamate—epilepsy syndrome	2.87e-05	0.00042	CcSEcCtD
Dabrafenib—Dermatitis—Vigabatrin—epilepsy syndrome	2.87e-05	0.00042	CcSEcCtD
Dabrafenib—Urethral disorder—Topiramate—epilepsy syndrome	2.87e-05	0.00042	CcSEcCtD
Dabrafenib—Pruritus—Oxcarbazepine—epilepsy syndrome	2.86e-05	0.000419	CcSEcCtD
Dabrafenib—Hypersensitivity—Carbamazepine—epilepsy syndrome	2.86e-05	0.000418	CcSEcCtD
Dabrafenib—Vision blurred—Gabapentin—epilepsy syndrome	2.85e-05	0.000418	CcSEcCtD
Dabrafenib—Headache—Vigabatrin—epilepsy syndrome	2.85e-05	0.000417	CcSEcCtD
Dabrafenib—Hypertension—Pregabalin—epilepsy syndrome	2.85e-05	0.000417	CcSEcCtD
Dabrafenib—Vomiting—Diazepam—epilepsy syndrome	2.85e-05	0.000417	CcSEcCtD
Dabrafenib—Rash—Diazepam—epilepsy syndrome	2.83e-05	0.000414	CcSEcCtD
Dabrafenib—Dermatitis—Diazepam—epilepsy syndrome	2.82e-05	0.000413	CcSEcCtD
Dabrafenib—Arthralgia—Pregabalin—epilepsy syndrome	2.81e-05	0.000411	CcSEcCtD
Dabrafenib—Myalgia—Pregabalin—epilepsy syndrome	2.81e-05	0.000411	CcSEcCtD
Dabrafenib—Dizziness—Zonisamide—epilepsy syndrome	2.81e-05	0.000411	CcSEcCtD
Dabrafenib—Headache—Diazepam—epilepsy syndrome	2.81e-05	0.000411	CcSEcCtD
Dabrafenib—Diarrhoea—Clonazepam—epilepsy syndrome	2.8e-05	0.00041	CcSEcCtD
Dabrafenib—Anaemia—Gabapentin—epilepsy syndrome	2.8e-05	0.000409	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	2.79e-05	0.000408	CcSEcCtD
Dabrafenib—Hypotension—Valproic Acid—epilepsy syndrome	2.78e-05	0.000408	CcSEcCtD
Dabrafenib—Asthenia—Carbamazepine—epilepsy syndrome	2.78e-05	0.000407	CcSEcCtD
Dabrafenib—Diarrhoea—Phenytoin—epilepsy syndrome	2.78e-05	0.000407	CcSEcCtD
Dabrafenib—Nausea—Fosphenytoin—epilepsy syndrome	2.77e-05	0.000406	CcSEcCtD
Dabrafenib—Diarrhoea—Oxcarbazepine—epilepsy syndrome	2.77e-05	0.000405	CcSEcCtD
Dabrafenib—Hypersensitivity—Lamotrigine—epilepsy syndrome	2.76e-05	0.000404	CcSEcCtD
Dabrafenib—Vomiting—Felbamate—epilepsy syndrome	2.76e-05	0.000404	CcSEcCtD
Dabrafenib—Dry mouth—Pregabalin—epilepsy syndrome	2.75e-05	0.000402	CcSEcCtD
Dabrafenib—Pruritus—Carbamazepine—epilepsy syndrome	2.74e-05	0.000402	CcSEcCtD
Dabrafenib—Rash—Felbamate—epilepsy syndrome	2.73e-05	0.0004	CcSEcCtD
Dabrafenib—Eye disorder—Topiramate—epilepsy syndrome	2.73e-05	0.0004	CcSEcCtD
Dabrafenib—Dermatitis—Felbamate—epilepsy syndrome	2.73e-05	0.0004	CcSEcCtD
Dabrafenib—Headache—Felbamate—epilepsy syndrome	2.72e-05	0.000398	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	2.71e-05	0.000397	CcSEcCtD
Dabrafenib—Leukopenia—Gabapentin—epilepsy syndrome	2.71e-05	0.000397	CcSEcCtD
Dabrafenib—Dizziness—Clonazepam—epilepsy syndrome	2.71e-05	0.000396	CcSEcCtD
Dabrafenib—Nausea—Vigabatrin—epilepsy syndrome	2.7e-05	0.000396	CcSEcCtD
Dabrafenib—Vomiting—Zonisamide—epilepsy syndrome	2.7e-05	0.000395	CcSEcCtD
Dabrafenib—Insomnia—Valproic Acid—epilepsy syndrome	2.69e-05	0.000394	CcSEcCtD
Dabrafenib—Oedema—Pregabalin—epilepsy syndrome	2.69e-05	0.000394	CcSEcCtD
Dabrafenib—Asthenia—Lamotrigine—epilepsy syndrome	2.69e-05	0.000394	CcSEcCtD
Dabrafenib—Dizziness—Phenytoin—epilepsy syndrome	2.69e-05	0.000393	CcSEcCtD
Dabrafenib—Rash—Zonisamide—epilepsy syndrome	2.68e-05	0.000392	CcSEcCtD
Dabrafenib—Infection—Pregabalin—epilepsy syndrome	2.68e-05	0.000392	CcSEcCtD
Dabrafenib—Dermatitis—Zonisamide—epilepsy syndrome	2.67e-05	0.000391	CcSEcCtD
Dabrafenib—Dizziness—Oxcarbazepine—epilepsy syndrome	2.67e-05	0.000391	CcSEcCtD
Dabrafenib—Nausea—Diazepam—epilepsy syndrome	2.66e-05	0.00039	CcSEcCtD
Dabrafenib—Headache—Zonisamide—epilepsy syndrome	2.66e-05	0.000389	CcSEcCtD
Dabrafenib—Diarrhoea—Carbamazepine—epilepsy syndrome	2.65e-05	0.000389	CcSEcCtD
Dabrafenib—Angiopathy—Topiramate—epilepsy syndrome	2.65e-05	0.000388	CcSEcCtD
Dabrafenib—Pruritus—Lamotrigine—epilepsy syndrome	2.65e-05	0.000388	CcSEcCtD
Dabrafenib—Immune system disorder—Topiramate—epilepsy syndrome	2.64e-05	0.000387	CcSEcCtD
Dabrafenib—Nervous system disorder—Pregabalin—epilepsy syndrome	2.64e-05	0.000387	CcSEcCtD
Dabrafenib—Cough—Gabapentin—epilepsy syndrome	2.64e-05	0.000387	CcSEcCtD
Dabrafenib—Thrombocytopenia—Pregabalin—epilepsy syndrome	2.64e-05	0.000386	CcSEcCtD
Dabrafenib—Mediastinal disorder—Topiramate—epilepsy syndrome	2.64e-05	0.000386	CcSEcCtD
Dabrafenib—Chills—Topiramate—epilepsy syndrome	2.62e-05	0.000384	CcSEcCtD
Dabrafenib—Skin disorder—Pregabalin—epilepsy syndrome	2.62e-05	0.000383	CcSEcCtD
Dabrafenib—Hypertension—Gabapentin—epilepsy syndrome	2.61e-05	0.000382	CcSEcCtD
Dabrafenib—Hyperhidrosis—Pregabalin—epilepsy syndrome	2.6e-05	0.000381	CcSEcCtD
Dabrafenib—Vomiting—Clonazepam—epilepsy syndrome	2.6e-05	0.000381	CcSEcCtD
Dabrafenib—Decreased appetite—Valproic Acid—epilepsy syndrome	2.59e-05	0.000379	CcSEcCtD
Dabrafenib—Alopecia—Topiramate—epilepsy syndrome	2.58e-05	0.000378	CcSEcCtD
Dabrafenib—Vomiting—Phenytoin—epilepsy syndrome	2.58e-05	0.000378	CcSEcCtD
Dabrafenib—Rash—Clonazepam—epilepsy syndrome	2.58e-05	0.000378	CcSEcCtD
Dabrafenib—Dermatitis—Clonazepam—epilepsy syndrome	2.58e-05	0.000377	CcSEcCtD
Dabrafenib—Myalgia—Gabapentin—epilepsy syndrome	2.58e-05	0.000377	CcSEcCtD
Dabrafenib—Arthralgia—Gabapentin—epilepsy syndrome	2.58e-05	0.000377	CcSEcCtD
Dabrafenib—Nausea—Felbamate—epilepsy syndrome	2.58e-05	0.000377	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	2.57e-05	0.000377	CcSEcCtD
Dabrafenib—Vomiting—Oxcarbazepine—epilepsy syndrome	2.57e-05	0.000376	CcSEcCtD
Dabrafenib—Fatigue—Valproic Acid—epilepsy syndrome	2.57e-05	0.000376	CcSEcCtD
Dabrafenib—Dizziness—Carbamazepine—epilepsy syndrome	2.57e-05	0.000376	CcSEcCtD
Dabrafenib—Diarrhoea—Lamotrigine—epilepsy syndrome	2.57e-05	0.000376	CcSEcCtD
Dabrafenib—Headache—Clonazepam—epilepsy syndrome	2.56e-05	0.000375	CcSEcCtD
Dabrafenib—Rash—Phenytoin—epilepsy syndrome	2.56e-05	0.000375	CcSEcCtD
Dabrafenib—Mental disorder—Topiramate—epilepsy syndrome	2.56e-05	0.000375	CcSEcCtD
Dabrafenib—Dermatitis—Phenytoin—epilepsy syndrome	2.56e-05	0.000375	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	2.56e-05	0.000375	CcSEcCtD
Dabrafenib—Rash—Oxcarbazepine—epilepsy syndrome	2.55e-05	0.000373	CcSEcCtD
Dabrafenib—Constipation—Valproic Acid—epilepsy syndrome	2.55e-05	0.000373	CcSEcCtD
Dabrafenib—Dermatitis—Oxcarbazepine—epilepsy syndrome	2.55e-05	0.000373	CcSEcCtD
Dabrafenib—Headache—Phenytoin—epilepsy syndrome	2.55e-05	0.000373	CcSEcCtD
Dabrafenib—Erythema—Topiramate—epilepsy syndrome	2.55e-05	0.000373	CcSEcCtD
Dabrafenib—Malnutrition—Topiramate—epilepsy syndrome	2.55e-05	0.000373	CcSEcCtD
Dabrafenib—Headache—Oxcarbazepine—epilepsy syndrome	2.53e-05	0.000371	CcSEcCtD
Dabrafenib—Nausea—Zonisamide—epilepsy syndrome	2.52e-05	0.000369	CcSEcCtD
Dabrafenib—Dry mouth—Gabapentin—epilepsy syndrome	2.52e-05	0.000369	CcSEcCtD
Dabrafenib—Hypotension—Pregabalin—epilepsy syndrome	2.52e-05	0.000368	CcSEcCtD
Dabrafenib—Dizziness—Lamotrigine—epilepsy syndrome	2.48e-05	0.000363	CcSEcCtD
Dabrafenib—Oedema—Gabapentin—epilepsy syndrome	2.47e-05	0.000362	CcSEcCtD
Dabrafenib—Vomiting—Carbamazepine—epilepsy syndrome	2.47e-05	0.000361	CcSEcCtD
Dabrafenib—Back pain—Topiramate—epilepsy syndrome	2.46e-05	0.000361	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	2.45e-05	0.000359	CcSEcCtD
Dabrafenib—Infection—Gabapentin—epilepsy syndrome	2.45e-05	0.000359	CcSEcCtD
Dabrafenib—Muscle spasms—Topiramate—epilepsy syndrome	2.45e-05	0.000358	CcSEcCtD
Dabrafenib—Rash—Carbamazepine—epilepsy syndrome	2.45e-05	0.000358	CcSEcCtD
Dabrafenib—Dermatitis—Carbamazepine—epilepsy syndrome	2.44e-05	0.000358	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	2.44e-05	0.000357	CcSEcCtD
Dabrafenib—Insomnia—Pregabalin—epilepsy syndrome	2.44e-05	0.000357	CcSEcCtD
Dabrafenib—Nausea—Clonazepam—epilepsy syndrome	2.43e-05	0.000356	CcSEcCtD
Dabrafenib—Headache—Carbamazepine—epilepsy syndrome	2.43e-05	0.000356	CcSEcCtD
Dabrafenib—Nervous system disorder—Gabapentin—epilepsy syndrome	2.42e-05	0.000355	CcSEcCtD
Dabrafenib—Thrombocytopenia—Gabapentin—epilepsy syndrome	2.42e-05	0.000354	CcSEcCtD
Dabrafenib—Nausea—Phenytoin—epilepsy syndrome	2.41e-05	0.000353	CcSEcCtD
Dabrafenib—Nausea—Oxcarbazepine—epilepsy syndrome	2.4e-05	0.000352	CcSEcCtD
Dabrafenib—Vision blurred—Topiramate—epilepsy syndrome	2.4e-05	0.000351	CcSEcCtD
Dabrafenib—Skin disorder—Gabapentin—epilepsy syndrome	2.4e-05	0.000351	CcSEcCtD
Dabrafenib—Hyperhidrosis—Gabapentin—epilepsy syndrome	2.39e-05	0.00035	CcSEcCtD
Dabrafenib—Vomiting—Lamotrigine—epilepsy syndrome	2.38e-05	0.000349	CcSEcCtD
Dabrafenib—Rash—Lamotrigine—epilepsy syndrome	2.36e-05	0.000346	CcSEcCtD
Dabrafenib—Dermatitis—Lamotrigine—epilepsy syndrome	2.36e-05	0.000346	CcSEcCtD
Dabrafenib—Abdominal pain—Valproic Acid—epilepsy syndrome	2.36e-05	0.000345	CcSEcCtD
Dabrafenib—Body temperature increased—Valproic Acid—epilepsy syndrome	2.36e-05	0.000345	CcSEcCtD
Dabrafenib—Anaemia—Topiramate—epilepsy syndrome	2.35e-05	0.000344	CcSEcCtD
Dabrafenib—Headache—Lamotrigine—epilepsy syndrome	2.35e-05	0.000344	CcSEcCtD
Dabrafenib—Decreased appetite—Pregabalin—epilepsy syndrome	2.34e-05	0.000343	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	2.33e-05	0.00034	CcSEcCtD
Dabrafenib—Fatigue—Pregabalin—epilepsy syndrome	2.32e-05	0.00034	CcSEcCtD
Dabrafenib—Hypotension—Gabapentin—epilepsy syndrome	2.31e-05	0.000338	CcSEcCtD
Dabrafenib—Nausea—Carbamazepine—epilepsy syndrome	2.3e-05	0.000337	CcSEcCtD
Dabrafenib—Constipation—Pregabalin—epilepsy syndrome	2.3e-05	0.000337	CcSEcCtD
Dabrafenib—Leukopenia—Topiramate—epilepsy syndrome	2.28e-05	0.000334	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	2.25e-05	0.000329	CcSEcCtD
Dabrafenib—Insomnia—Gabapentin—epilepsy syndrome	2.23e-05	0.000327	CcSEcCtD
Dabrafenib—Nausea—Lamotrigine—epilepsy syndrome	2.23e-05	0.000326	CcSEcCtD
Dabrafenib—Cough—Topiramate—epilepsy syndrome	2.22e-05	0.000325	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Pregabalin—epilepsy syndrome	2.2e-05	0.000322	CcSEcCtD
Dabrafenib—Hypertension—Topiramate—epilepsy syndrome	2.2e-05	0.000322	CcSEcCtD
Dabrafenib—Hypersensitivity—Valproic Acid—epilepsy syndrome	2.2e-05	0.000321	CcSEcCtD
Dabrafenib—Arthralgia—Topiramate—epilepsy syndrome	2.17e-05	0.000317	CcSEcCtD
Dabrafenib—Myalgia—Topiramate—epilepsy syndrome	2.17e-05	0.000317	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	2.15e-05	0.000315	CcSEcCtD
Dabrafenib—Decreased appetite—Gabapentin—epilepsy syndrome	2.15e-05	0.000314	CcSEcCtD
Dabrafenib—Asthenia—Valproic Acid—epilepsy syndrome	2.14e-05	0.000313	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	2.13e-05	0.000312	CcSEcCtD
Dabrafenib—Fatigue—Gabapentin—epilepsy syndrome	2.13e-05	0.000312	CcSEcCtD
Dabrafenib—Abdominal pain—Pregabalin—epilepsy syndrome	2.13e-05	0.000312	CcSEcCtD
Dabrafenib—Body temperature increased—Pregabalin—epilepsy syndrome	2.13e-05	0.000312	CcSEcCtD
Dabrafenib—Dry mouth—Topiramate—epilepsy syndrome	2.12e-05	0.00031	CcSEcCtD
Dabrafenib—Constipation—Gabapentin—epilepsy syndrome	2.11e-05	0.000309	CcSEcCtD
Dabrafenib—Pruritus—Valproic Acid—epilepsy syndrome	2.11e-05	0.000309	CcSEcCtD
Dabrafenib—Oedema—Topiramate—epilepsy syndrome	2.08e-05	0.000304	CcSEcCtD
Dabrafenib—Infection—Topiramate—epilepsy syndrome	2.06e-05	0.000302	CcSEcCtD
Dabrafenib—Diarrhoea—Valproic Acid—epilepsy syndrome	2.04e-05	0.000298	CcSEcCtD
Dabrafenib—Nervous system disorder—Topiramate—epilepsy syndrome	2.04e-05	0.000298	CcSEcCtD
Dabrafenib—Thrombocytopenia—Topiramate—epilepsy syndrome	2.03e-05	0.000298	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Gabapentin—epilepsy syndrome	2.02e-05	0.000296	CcSEcCtD
Dabrafenib—Skin disorder—Topiramate—epilepsy syndrome	2.02e-05	0.000295	CcSEcCtD
Dabrafenib—Hyperhidrosis—Topiramate—epilepsy syndrome	2.01e-05	0.000294	CcSEcCtD
Dabrafenib—Hypersensitivity—Pregabalin—epilepsy syndrome	1.98e-05	0.00029	CcSEcCtD
Dabrafenib—Dizziness—Valproic Acid—epilepsy syndrome	1.97e-05	0.000288	CcSEcCtD
Dabrafenib—Abdominal pain—Gabapentin—epilepsy syndrome	1.95e-05	0.000286	CcSEcCtD
Dabrafenib—Body temperature increased—Gabapentin—epilepsy syndrome	1.95e-05	0.000286	CcSEcCtD
Dabrafenib—Hypotension—Topiramate—epilepsy syndrome	1.94e-05	0.000284	CcSEcCtD
Dabrafenib—Asthenia—Pregabalin—epilepsy syndrome	1.93e-05	0.000283	CcSEcCtD
Dabrafenib—Pruritus—Pregabalin—epilepsy syndrome	1.91e-05	0.000279	CcSEcCtD
Dabrafenib—Vomiting—Valproic Acid—epilepsy syndrome	1.89e-05	0.000277	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	1.89e-05	0.000277	CcSEcCtD
Dabrafenib—Insomnia—Topiramate—epilepsy syndrome	1.88e-05	0.000275	CcSEcCtD
Dabrafenib—Rash—Valproic Acid—epilepsy syndrome	1.88e-05	0.000275	CcSEcCtD
Dabrafenib—Dermatitis—Valproic Acid—epilepsy syndrome	1.88e-05	0.000275	CcSEcCtD
Dabrafenib—Headache—Valproic Acid—epilepsy syndrome	1.87e-05	0.000273	CcSEcCtD
Dabrafenib—Diarrhoea—Pregabalin—epilepsy syndrome	1.84e-05	0.00027	CcSEcCtD
Dabrafenib—Hypersensitivity—Gabapentin—epilepsy syndrome	1.82e-05	0.000266	CcSEcCtD
Dabrafenib—Decreased appetite—Topiramate—epilepsy syndrome	1.81e-05	0.000264	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Topiramate—epilepsy syndrome	1.79e-05	0.000263	CcSEcCtD
Dabrafenib—Fatigue—Topiramate—epilepsy syndrome	1.79e-05	0.000262	CcSEcCtD
Dabrafenib—Dizziness—Pregabalin—epilepsy syndrome	1.78e-05	0.000261	CcSEcCtD
Dabrafenib—Constipation—Topiramate—epilepsy syndrome	1.78e-05	0.00026	CcSEcCtD
Dabrafenib—Asthenia—Gabapentin—epilepsy syndrome	1.77e-05	0.000259	CcSEcCtD
Dabrafenib—Nausea—Valproic Acid—epilepsy syndrome	1.77e-05	0.000259	CcSEcCtD
Dabrafenib—Pruritus—Gabapentin—epilepsy syndrome	1.75e-05	0.000256	CcSEcCtD
Dabrafenib—Vomiting—Pregabalin—epilepsy syndrome	1.71e-05	0.000251	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Topiramate—epilepsy syndrome	1.7e-05	0.000249	CcSEcCtD
Dabrafenib—Rash—Pregabalin—epilepsy syndrome	1.7e-05	0.000249	CcSEcCtD
Dabrafenib—Dermatitis—Pregabalin—epilepsy syndrome	1.7e-05	0.000248	CcSEcCtD
Dabrafenib—Diarrhoea—Gabapentin—epilepsy syndrome	1.69e-05	0.000247	CcSEcCtD
Dabrafenib—Headache—Pregabalin—epilepsy syndrome	1.69e-05	0.000247	CcSEcCtD
Dabrafenib—Abdominal pain—Topiramate—epilepsy syndrome	1.64e-05	0.00024	CcSEcCtD
Dabrafenib—Body temperature increased—Topiramate—epilepsy syndrome	1.64e-05	0.00024	CcSEcCtD
Dabrafenib—Dizziness—Gabapentin—epilepsy syndrome	1.63e-05	0.000239	CcSEcCtD
Dabrafenib—Nausea—Pregabalin—epilepsy syndrome	1.6e-05	0.000234	CcSEcCtD
Dabrafenib—Vomiting—Gabapentin—epilepsy syndrome	1.57e-05	0.00023	CcSEcCtD
Dabrafenib—Rash—Gabapentin—epilepsy syndrome	1.56e-05	0.000228	CcSEcCtD
Dabrafenib—Dermatitis—Gabapentin—epilepsy syndrome	1.56e-05	0.000228	CcSEcCtD
Dabrafenib—Headache—Gabapentin—epilepsy syndrome	1.55e-05	0.000227	CcSEcCtD
Dabrafenib—Hypersensitivity—Topiramate—epilepsy syndrome	1.53e-05	0.000224	CcSEcCtD
Dabrafenib—Asthenia—Topiramate—epilepsy syndrome	1.49e-05	0.000218	CcSEcCtD
Dabrafenib—Pruritus—Topiramate—epilepsy syndrome	1.47e-05	0.000215	CcSEcCtD
Dabrafenib—Nausea—Gabapentin—epilepsy syndrome	1.47e-05	0.000215	CcSEcCtD
Dabrafenib—Diarrhoea—Topiramate—epilepsy syndrome	1.42e-05	0.000208	CcSEcCtD
Dabrafenib—Dizziness—Topiramate—epilepsy syndrome	1.37e-05	0.000201	CcSEcCtD
Dabrafenib—Vomiting—Topiramate—epilepsy syndrome	1.32e-05	0.000193	CcSEcCtD
Dabrafenib—Rash—Topiramate—epilepsy syndrome	1.31e-05	0.000192	CcSEcCtD
Dabrafenib—Dermatitis—Topiramate—epilepsy syndrome	1.31e-05	0.000192	CcSEcCtD
Dabrafenib—Headache—Topiramate—epilepsy syndrome	1.3e-05	0.000191	CcSEcCtD
Dabrafenib—Nausea—Topiramate—epilepsy syndrome	1.23e-05	0.000181	CcSEcCtD
Dabrafenib—BRAF—Signaling Pathways—FYN—epilepsy syndrome	1.82e-06	3.33e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—H2AFX—epilepsy syndrome	1.81e-06	3.32e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—AGT—epilepsy syndrome	1.81e-06	3.32e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MEF2C—epilepsy syndrome	1.81e-06	3.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCR2—epilepsy syndrome	1.8e-06	3.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SST—epilepsy syndrome	1.8e-06	3.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NTRK2—epilepsy syndrome	1.8e-06	3.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FYN—epilepsy syndrome	1.79e-06	3.29e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—epilepsy syndrome	1.79e-06	3.28e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—H2AFX—epilepsy syndrome	1.79e-06	3.28e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—DUSP6—epilepsy syndrome	1.79e-06	3.28e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CACNA1D—epilepsy syndrome	1.79e-06	3.28e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—epilepsy syndrome	1.78e-06	3.26e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—APOE—epilepsy syndrome	1.77e-06	3.25e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ADRA2A—epilepsy syndrome	1.76e-06	3.24e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—SRC—epilepsy syndrome	1.76e-06	3.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PLAT—epilepsy syndrome	1.76e-06	3.22e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—SLC2A1—epilepsy syndrome	1.75e-06	3.21e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—YWHAZ—epilepsy syndrome	1.75e-06	3.2e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—COX3—epilepsy syndrome	1.74e-06	3.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—JUN—epilepsy syndrome	1.73e-06	3.18e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—epilepsy syndrome	1.73e-06	3.17e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PLCB1—epilepsy syndrome	1.73e-06	3.17e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—SRC—epilepsy syndrome	1.73e-06	3.17e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NGF—epilepsy syndrome	1.73e-06	3.17e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—YWHAZ—epilepsy syndrome	1.72e-06	3.16e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—TH—epilepsy syndrome	1.72e-06	3.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—VEGFA—epilepsy syndrome	1.72e-06	3.15e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL12—epilepsy syndrome	1.69e-06	3.11e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—BDKRB2—epilepsy syndrome	1.69e-06	3.11e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—AKT1—epilepsy syndrome	1.69e-06	3.11e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PRKCB—epilepsy syndrome	1.69e-06	3.1e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—KCNJ11—epilepsy syndrome	1.68e-06	3.09e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CHRM3—epilepsy syndrome	1.68e-06	3.09e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—VEGFA—epilepsy syndrome	1.68e-06	3.09e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6ST—epilepsy syndrome	1.68e-06	3.08e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCR5—epilepsy syndrome	1.68e-06	3.08e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TXNRD1—epilepsy syndrome	1.67e-06	3.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TSC2—epilepsy syndrome	1.67e-06	3.06e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CRP—epilepsy syndrome	1.67e-06	3.06e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—JUNB—epilepsy syndrome	1.66e-06	3.05e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CNR1—epilepsy syndrome	1.66e-06	3.05e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—HMOX1—epilepsy syndrome	1.66e-06	3.05e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CCR5—epilepsy syndrome	1.66e-06	3.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PLCB1—epilepsy syndrome	1.66e-06	3.04e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—FGF2—epilepsy syndrome	1.66e-06	3.04e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—KCNB1—epilepsy syndrome	1.65e-06	3.03e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PFKL—epilepsy syndrome	1.65e-06	3.03e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CACNA2D2—epilepsy syndrome	1.65e-06	3.03e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLCO1A2—epilepsy syndrome	1.65e-06	3.03e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC6A8—epilepsy syndrome	1.65e-06	3.03e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—AVP—epilepsy syndrome	1.64e-06	3.02e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HTR2A—epilepsy syndrome	1.64e-06	3.01e-05	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—AKT1—epilepsy syndrome	1.63e-06	2.99e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HTR7—epilepsy syndrome	1.62e-06	2.98e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AQP1—epilepsy syndrome	1.62e-06	2.98e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HBEGF—epilepsy syndrome	1.58e-06	2.89e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	1.57e-06	2.88e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TSC2—epilepsy syndrome	1.56e-06	2.86e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AGT—epilepsy syndrome	1.56e-06	2.86e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—SRC—epilepsy syndrome	1.56e-06	2.85e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—HMOX1—epilepsy syndrome	1.55e-06	2.85e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKT3—epilepsy syndrome	1.55e-06	2.84e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TSC2—epilepsy syndrome	1.54e-06	2.83e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PRKCB—epilepsy syndrome	1.54e-06	2.83e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—POMC—epilepsy syndrome	1.54e-06	2.82e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	1.54e-06	2.82e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6ST—epilepsy syndrome	1.54e-06	2.82e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CAT—epilepsy syndrome	1.53e-06	2.81e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—APOE—epilepsy syndrome	1.53e-06	2.8e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—POMC—epilepsy syndrome	1.52e-06	2.79e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ADAM10—epilepsy syndrome	1.51e-06	2.77e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—APOE—epilepsy syndrome	1.51e-06	2.77e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MTOR—epilepsy syndrome	1.51e-06	2.77e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—UPB1—epilepsy syndrome	1.51e-06	2.77e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ATIC—epilepsy syndrome	1.51e-06	2.77e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NEU1—epilepsy syndrome	1.51e-06	2.77e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCL2—epilepsy syndrome	1.5e-06	2.76e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KDR—epilepsy syndrome	1.5e-06	2.75e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTGS2—epilepsy syndrome	1.49e-06	2.74e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—SRC—epilepsy syndrome	1.49e-06	2.74e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ABCB1—epilepsy syndrome	1.49e-06	2.73e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—epilepsy syndrome	1.48e-06	2.72e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TNF—epilepsy syndrome	1.47e-06	2.7e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—KCNJ11—epilepsy syndrome	1.47e-06	2.69e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CHRM3—epilepsy syndrome	1.47e-06	2.69e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HSD17B4—epilepsy syndrome	1.45e-06	2.66e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PRKCB—epilepsy syndrome	1.44e-06	2.64e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—HMOX1—epilepsy syndrome	1.44e-06	2.64e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6ST—epilepsy syndrome	1.43e-06	2.63e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—S100B—epilepsy syndrome	1.43e-06	2.62e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CAT—epilepsy syndrome	1.42e-06	2.6e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6ST—epilepsy syndrome	1.42e-06	2.6e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SOCS3—epilepsy syndrome	1.41e-06	2.6e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDC42—epilepsy syndrome	1.41e-06	2.59e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FOS—epilepsy syndrome	1.41e-06	2.58e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NOS2—epilepsy syndrome	1.41e-06	2.58e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GBE1—epilepsy syndrome	1.4e-06	2.57e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPP1R3C—epilepsy syndrome	1.4e-06	2.57e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ALB—epilepsy syndrome	1.39e-06	2.55e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GPX1—epilepsy syndrome	1.39e-06	2.54e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ABCB1—epilepsy syndrome	1.38e-06	2.53e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CASP8—epilepsy syndrome	1.37e-06	2.52e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ABCG2—epilepsy syndrome	1.37e-06	2.52e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AVP—epilepsy syndrome	1.37e-06	2.51e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP2C19—epilepsy syndrome	1.34e-06	2.45e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP11A1—epilepsy syndrome	1.33e-06	2.44e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	1.32e-06	2.42e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ASAH1—epilepsy syndrome	1.32e-06	2.42e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—POMC—epilepsy syndrome	1.31e-06	2.41e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HES1—epilepsy syndrome	1.29e-06	2.37e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCL2—epilepsy syndrome	1.28e-06	2.36e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GPX1—epilepsy syndrome	1.28e-06	2.35e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—STXBP1—epilepsy syndrome	1.28e-06	2.35e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FYN—epilepsy syndrome	1.26e-06	2.3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—H2AFX—epilepsy syndrome	1.25e-06	2.3e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NT5E—epilepsy syndrome	1.25e-06	2.29e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALAD—epilepsy syndrome	1.25e-06	2.29e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MEF2C—epilepsy syndrome	1.25e-06	2.29e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—FGF2—epilepsy syndrome	1.24e-06	2.28e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AGT—epilepsy syndrome	1.22e-06	2.23e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTGS2—epilepsy syndrome	1.21e-06	2.23e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—SRC—epilepsy syndrome	1.21e-06	2.22e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—YWHAZ—epilepsy syndrome	1.21e-06	2.22e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	1.2e-06	2.21e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP2D6—epilepsy syndrome	1.2e-06	2.2e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ABCG2—epilepsy syndrome	1.2e-06	2.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NGF—epilepsy syndrome	1.19e-06	2.19e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALDH7A1—epilepsy syndrome	1.19e-06	2.19e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CACNA1A—epilepsy syndrome	1.19e-06	2.19e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—APOE—epilepsy syndrome	1.19e-06	2.18e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—BCL2—epilepsy syndrome	1.18e-06	2.16e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ST3GAL3—epilepsy syndrome	1.17e-06	2.14e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP2C19—epilepsy syndrome	1.17e-06	2.14e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCR5—epilepsy syndrome	1.16e-06	2.13e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FGF2—epilepsy syndrome	1.16e-06	2.13e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP11A1—epilepsy syndrome	1.16e-06	2.12e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—RELA—epilepsy syndrome	1.15e-06	2.11e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—FGF2—epilepsy syndrome	1.15e-06	2.1e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ADSL—epilepsy syndrome	1.14e-06	2.1e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ADRA2A—epilepsy syndrome	1.14e-06	2.1e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—BCHE—epilepsy syndrome	1.14e-06	2.09e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HTR2A—epilepsy syndrome	1.14e-06	2.09e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MTOR—epilepsy syndrome	1.13e-06	2.07e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AGT—epilepsy syndrome	1.13e-06	2.06e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GLUL—epilepsy syndrome	1.12e-06	2.06e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—epilepsy syndrome	1.1e-06	2.03e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—APOE—epilepsy syndrome	1.1e-06	2.02e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CACNA1D—epilepsy syndrome	1.1e-06	2.02e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—AKT1—epilepsy syndrome	1.09e-06	2.01e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SLC2A1—epilepsy syndrome	1.08e-06	1.99e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TSC2—epilepsy syndrome	1.08e-06	1.98e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AGT—epilepsy syndrome	1.08e-06	1.98e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—RELA—epilepsy syndrome	1.08e-06	1.98e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—AKT1—epilepsy syndrome	1.07e-06	1.97e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PLCB1—epilepsy syndrome	1.07e-06	1.97e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—TH—epilepsy syndrome	1.07e-06	1.96e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APOE—epilepsy syndrome	1.06e-06	1.94e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MTOR—epilepsy syndrome	1.06e-06	1.94e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.05e-06	1.93e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP2D6—epilepsy syndrome	1.05e-06	1.92e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MTOR—epilepsy syndrome	1.04e-06	1.91e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL1B—epilepsy syndrome	1.04e-06	1.91e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KDR—epilepsy syndrome	1.04e-06	1.9e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTGS2—epilepsy syndrome	1.03e-06	1.9e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TXNRD1—epilepsy syndrome	1.03e-06	1.89e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—POMC—epilepsy syndrome	1.02e-06	1.88e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—JUN—epilepsy syndrome	1.01e-06	1.85e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AQP1—epilepsy syndrome	9.99e-07	1.83e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—ALB—epilepsy syndrome	9.97e-07	1.83e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PRKCB—epilepsy syndrome	9.97e-07	1.83e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ADRA2A—epilepsy syndrome	9.95e-07	1.83e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6ST—epilepsy syndrome	9.93e-07	1.82e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—BCHE—epilepsy syndrome	9.91e-07	1.82e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CASP3—epilepsy syndrome	9.72e-07	1.78e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—AKT1—epilepsy syndrome	9.66e-07	1.77e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—POMC—epilepsy syndrome	9.47e-07	1.74e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC2A1—epilepsy syndrome	9.45e-07	1.73e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—JUN—epilepsy syndrome	9.44e-07	1.73e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PLCB1—epilepsy syndrome	9.35e-07	1.72e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ALB—epilepsy syndrome	9.32e-07	1.71e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TH—epilepsy syndrome	9.31e-07	1.71e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—AKT1—epilepsy syndrome	9.28e-07	1.7e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MMP9—epilepsy syndrome	9.18e-07	1.68e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—POMC—epilepsy syndrome	9.08e-07	1.67e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—SRC—epilepsy syndrome	9.06e-07	1.66e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—KCNJ11—epilepsy syndrome	9.04e-07	1.66e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CHRM3—epilepsy syndrome	9.04e-07	1.66e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—HMOX1—epilepsy syndrome	8.92e-07	1.64e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL2—epilepsy syndrome	8.88e-07	1.63e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CAT—epilepsy syndrome	8.8e-07	1.62e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ALB—epilepsy syndrome	8.63e-07	1.58e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ABCB1—epilepsy syndrome	8.57e-07	1.57e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SRC—epilepsy syndrome	8.46e-07	1.55e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SRC—epilepsy syndrome	8.36e-07	1.53e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—epilepsy syndrome	8.24e-07	1.51e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTGS2—epilepsy syndrome	8.16e-07	1.5e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGF2—epilepsy syndrome	8.03e-07	1.47e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GPX1—epilepsy syndrome	7.96e-07	1.46e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HMOX1—epilepsy syndrome	7.77e-07	1.43e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CAT—epilepsy syndrome	7.67e-07	1.41e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTGS2—epilepsy syndrome	7.55e-07	1.39e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—AKT1—epilepsy syndrome	7.51e-07	1.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RELA—epilepsy syndrome	7.45e-07	1.37e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCG2—epilepsy syndrome	7.37e-07	1.35e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MTOR—epilepsy syndrome	7.31e-07	1.34e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP2C19—epilepsy syndrome	7.18e-07	1.32e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP11A1—epilepsy syndrome	7.13e-07	1.31e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AGT—epilepsy syndrome	6.98e-07	1.28e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GPX1—epilepsy syndrome	6.94e-07	1.27e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—APOE—epilepsy syndrome	6.84e-07	1.26e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CASP3—epilepsy syndrome	6.72e-07	1.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—JUN—epilepsy syndrome	6.53e-07	1.2e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP2D6—epilepsy syndrome	6.44e-07	1.18e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP9—epilepsy syndrome	6.35e-07	1.17e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AKT1—epilepsy syndrome	6.16e-07	1.13e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ADRA2A—epilepsy syndrome	6.13e-07	1.12e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—BCHE—epilepsy syndrome	6.1e-07	1.12e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—AKT1—epilepsy syndrome	6.1e-07	1.12e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AGT—epilepsy syndrome	6.08e-07	1.12e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—APOE—epilepsy syndrome	5.96e-07	1.09e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—POMC—epilepsy syndrome	5.88e-07	1.08e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SRC—epilepsy syndrome	5.86e-07	1.07e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC2A1—epilepsy syndrome	5.82e-07	1.07e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PLCB1—epilepsy syndrome	5.76e-07	1.06e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TH—epilepsy syndrome	5.74e-07	1.05e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—epilepsy syndrome	5.7e-07	1.05e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—AKT1—epilepsy syndrome	5.63e-07	1.03e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ALB—epilepsy syndrome	5.36e-07	9.83e-06	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AKT1—epilepsy syndrome	5.26e-07	9.65e-06	CbGpPWpGaD
Dabrafenib—RAF1—Disease—AKT1—epilepsy syndrome	5.2e-07	9.54e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—POMC—epilepsy syndrome	5.12e-07	9.39e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HMOX1—epilepsy syndrome	4.79e-07	8.79e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CAT—epilepsy syndrome	4.73e-07	8.67e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS2—epilepsy syndrome	4.69e-07	8.6e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ALB—epilepsy syndrome	4.67e-07	8.56e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCB1—epilepsy syndrome	4.6e-07	8.43e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GPX1—epilepsy syndrome	4.27e-07	7.84e-06	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AKT1—epilepsy syndrome	4.1e-07	7.52e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS2—epilepsy syndrome	4.08e-07	7.49e-06	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AKT1—epilepsy syndrome	3.8e-07	6.97e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AGT—epilepsy syndrome	3.75e-07	6.88e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOE—epilepsy syndrome	3.67e-07	6.74e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKT1—epilepsy syndrome	3.64e-07	6.68e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—POMC—epilepsy syndrome	3.15e-07	5.79e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALB—epilepsy syndrome	2.88e-07	5.28e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS2—epilepsy syndrome	2.52e-07	4.62e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AKT1—epilepsy syndrome	2.36e-07	4.32e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AKT1—epilepsy syndrome	2.05e-07	3.77e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKT1—epilepsy syndrome	1.26e-07	2.32e-06	CbGpPWpGaD
